Storia in 5 fonti

Incyte to buy blood disorder drug in possibly $2B deal

Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

Incyte to buy blood disorder drug in possibly $2B deal

Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.

originale

Timeline cronologica

lunedì 8 giugno 2026·biopharmadive.com
Incyte to buy blood disorder drug in possibly $2B deal
Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
lunedì 8 giugno 2026·morningstar.com
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding…
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

Incyte to buy blood disorder drug in possibly $2B deal

Confronto fonti

Incyte to buy blood disorder drug in possibly $2B deal

Timeline cronologica

Incyte to buy blood disorder drug in possibly $2B deal

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding…

Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential - Incyte (NASDAQ:INCY

Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology…

Incyte compra Vega Therapeutics por até US$ 2 bi para expandir portfólio em hematologia

Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal

Incyte compra Vega Therapeutics por até US$ 2 bi para expandir portfólio em hematologia

Incyte's Meury, now a buyer, sees $2B Vega deal as a step in blood treatments beyond Jakafi

Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential - Incyte (NASDAQ:INCY